1. Introduction {#sec1-nutrients-12-01933}
===============

The proliferation of satellite cells and vascularization are the essential processes in the regeneration of injured skeletal muscles. Myogenesis and angiogenesis are a prerequisite for the subsequent morphological and functional healing of the injured muscle. This, in turn, leads to rebuilding of the damaged myocytes and vessels, restoration of the blood flow and oxygen supply to the tissue. Nitric oxide (NO) plays a key role in repair response by inducing gene expression for several growth factors such as FGF, VEGF, IGF-1, HGF, PDGF^BB^ and BDNF, which are extracellular signals regulating the functions of the muscular, vascular and nervous systems. NO is produced from L-arginine by three isoenzymes called nitric oxide synthases (NOS), all present in skeletal muscles. While neuronal NOS (nNOS) and endothelial NOS (eNOS) are isoforms expressed constitutively, inducible NOS (iNOS) is mainly expressed during inflammatory response. NO generation can be modulated by intense physical training (physiological hypoxia), altitude training or training in hypoxic conditions, NO donors or NO precursors such as L-arginine \[[@B1-nutrients-12-01933],[@B2-nutrients-12-01933],[@B3-nutrients-12-01933]\].

Over recent years, intermittent hypoxic exposure (IHE) has been introduced into sport. IHE is a method by which athletes are exposed to short bouts of severe hypoxia (9--12% O~2~), interspersed with periods of normal air. Available studies reported substantial improvement in sea level endurance and anaerobic performance after IHE \[[@B4-nutrients-12-01933],[@B5-nutrients-12-01933],[@B6-nutrients-12-01933]\]. Beside the effects that hypoxia exerts on physical performance, there is some evidence that IHE might be beneficial for vascular endothelial activity and muscle regenerative capacity \[[@B7-nutrients-12-01933],[@B8-nutrients-12-01933]\]. Hypoxic exposure increases production of reactive nitrogen and oxygen species (NO and H~2~O~2~) and affects metabolic pathways including mitochondrial respiration and biogenesis, apoptosis and, what has more recently been demonstrated, satellite cells proliferation. However, NO and H~2~O~2~ play a contradictory role in muscle regeneration and repair, i.e., in combination with growth factors, they lead to recovery of tissue function, whereas the local persistence of NO and H~2~O~2~ sustained by infiltrated neutrophils may cause further oxidative injury to differentiating myoblasts and myotubes, thereby delaying the complete health restoration \[[@B9-nutrients-12-01933],[@B10-nutrients-12-01933]\]. So far, little is known on hypoxic exposure in combination with high arginine intake and their influence on the muscle injury, repair and regeneration. The typical dietary intake of L-arginine is set at approx. 3--8 g per day. Extracellular L-arginine can be rapidly taken up by endothelial cells and oxidized to NO. In a few clinical trials, intravenous (single dose of 30 g within 30 min) or dietary administration of relatively large doses of L-arginine (15--16 g per day) has been shown to result in enhanced NO formation, especially in subjects with endothelial dysfunction \[[@B11-nutrients-12-01933]\]. L-arginine also participates in other metabolic pathways, which are independent of NO synthesis but essential for physical performance. For instance, as a potent hormone secretagogue, L-arginine increases plasma levels of insulin, glucagon, growth hormone, insulin-like growth factor 1 and catecholamines \[[@B12-nutrients-12-01933]\]. Additionally, L-arginine may be metabolized via arginase whose high concentrations are identified in healing wounds due to macrophage production. Arginase activity results in ornithine formation, which is a precursor for proline that serves as substrate for collagen synthesis. Therefore, arginine supplementation could have a multidirectional impact on tissue regenerative processes \[[@B13-nutrients-12-01933],[@B14-nutrients-12-01933]\]. On the basis of the gathered data, the present study was designed to explain whether hypoxic-induced NO and H~2~O~2~ generation contributes to the release of oxi-inflammatory mediators regulating the injury--repair--regeneration of skeletal muscles and to check whether high-dose L-arginine intake enhances NO and growth factors production during intermittent hypoxic exposure.

2. Materials and Methods {#sec2-nutrients-12-01933}
========================

2.1. Subjects {#sec2dot1-nutrients-12-01933}
-------------

Forty elite male wrestlers, members of the national team, were observed during preparatory periods for the new competition season (endurance training 53%, directed training 9% and special power training 38%). Each athlete underwent a thorough screening, including a full medical evaluation in National Centre for Sports Medicine. A two-week washout period was introduced before the training camp to avoid any possible interference of other nutritional supplements in the measured biochemical markers. Exclusion criteria included serious orthopaedic injury (*n* = 3), nutrition supplements or medications (*n* = 2), dehydration (*n* = 2) and anaemia (*n* = 1) identified at any point of the entire observation. Eventually, thirty-two athletes met all the criteria and completed the whole experiment ([Table 1](#nutrients-12-01933-t001){ref-type="table"}). The athletes participated in a 14-day training camp at the National Olympic Sport Centre. Prior to the training camp, the athletes were randomly assigned in a double-blind manner to a control group (placebo; methylcellulose capsules: 2 × 6 g per day for 12 days), an arginine group (Arg; capsules: 2 × 6 g per day for 12 days), a hypoxia group (IHE) and an arginine with hypoxic exposure group (Arg/IHE).

Throughout the camp, all athletes lived at the same accommodation and followed the same training schedule, sleeping time and diet. Daily energy value of food offered on the menu did not exceed 5200 kcal, and the protein dose varied from 1.6 to 1.8 g/kg of body mass. During the camp, the wrestlers consumed an isotonic sports drink Vitargo (osmolality 317 mOsm/kg H~2~O) or plain water. The dehydration level was assessed by Osmocheck calibrated in mOsm/kg H~2~O from 0 to 1500 mOsmols. All the subjects were informed of the aim of the study and signed a written consent to participate in the project. The protocol of the study was approved by the ethics committee at Medical University Poznan (N^o^550/11), in accordance with the Helsinki Declaration.

2.2. Arginine Supplementation {#sec2dot2-nutrients-12-01933}
-----------------------------

The flavour and appearance of arginine capsules (6 g capsules administered twice a day for 12 days) and placebo (methylcellulose capsules: 2 × 6 g per day for 12 days) were indistinguishable for both the subjects and the investigators. The subjects were instructed to consume their supplement 1 h before the morning training and 1 h before the afternoon training for 12 days of the training camp ([Figure 1](#nutrients-12-01933-f001){ref-type="fig"}). Arginine and placebo capsules were prepared by Nutrend (The Czech Republic).

2.3. Intermittent Hypoxic Exposure {#sec2dot3-nutrients-12-01933}
----------------------------------

The passive 12-day intermittent hypoxic exposure (IHE) was conducted under medical supervision according to the procedure by Hinickson et al. \[[@B15-nutrients-12-01933]\] using the GO~2~Altitude hypoxicator (Australia) at the Olympic Sports Centre ([Figure 1](#nutrients-12-01933-f001){ref-type="fig"}). The hypoxicator was able to simulate the height of 2500 to 6500 m above sea level by regulating oxygen levels at FiO~2~ of 14--9% (fraction of inspired oxygen). Intermittent hypoxic exposure parameters were determined after the preliminary assessment of athlete's ability to adapt to hypoxic gas mixtures. The hypoxic test included the measurements of the time for the blood saturation to drop to 85% with FiO~2~ = 12% (equivalent to 4500 m above sea level) and the time for the blood saturation to return to 95% in normoxia. Based on the hypoxic test results, the IHE protocol was determined for every athlete. IHE was applied once a day, at least 2 h after sports training. Each IHE session consisted of 6 doses of 3--8-min periods of hypoxia (at FiO~2~ of 14--12%) interrupted by 3--5-min periods of normoxia, and repeated for 60--80 min. Hypoxic exposure started with two sessions with the oxygen concentration in the mask at FiO~2~ of 13.5% (equivalent to \~3000 m above sea level) and then reduced the oxygen concentration to FiO~2~ of 12% (equivalent to \~4500 m above sea level). The blood saturation (SpO~2~) and heart rate (HR) were individually monitored during every IHE session. SpO~2~ oscillated from 90.8 ± 2.4% on 1st day to 91.4 ± 5.6% whereas HR oscillated from 76.0 ± 7.8 bpm on 1st day to 76.1 ± 11.8 bpm on in groups exposed to hypoxia.

2.4. Body Composition {#sec2dot4-nutrients-12-01933}
---------------------

Body mass (BM) and body composition: fat-free mass (FFM) and fat mass (FM) were estimated using Tanita Body Composition Analyser MC-418 (Japan) calibrated prior to each test session in accordance with the manufacturer's guidelines. Duplicate measures were taken with the participant in a standing position; the average value was used for the final analysis. The recurrence of measurement amounted to 98%. The measurements were taken between 7.00 and 8.00 a.m. before blood sampling.

2.5. Blood Sampling {#sec2dot5-nutrients-12-01933}
-------------------

Blood samples were taken 3-fold (on the 1st, 7th and 14th days of the training camp) from the median cubital vein between 7.00 and 8.00 a.m. after an overnight sleep, using S-Monovette tubes (Sarstedt, Austria). Within 20 min., they were centrifuged at 3000× *g* and +8 °C for 10 min. Aliquots of serum were stored at −80 °C. All samples were analysed in duplicate or triplicate in a single assay to avoid inter-assay variability. The intra-assay coefficients of variation (CV) for the used kits were \<5%.

2.6. Skeletal Muscle Damage {#sec2dot6-nutrients-12-01933}
---------------------------

Serum total creatine kinase (CK) activity was used as a marker of sarcolemma disruption and was evaluated by using commercially available reagents and mobile spectrophotometer DP 310 Vario II (Germany) at a temperature of 20--25 °C. The CK activity has been measured immediately after serum collection for the consecutive days of the conditioning camp. Percentage of changes in CK activity (%CK) was calculated by comparing the initial value on the 1st day with peak activity on the 7th and the 14th days of the conditioning camp.

2.7. Oxi-Inflammatory Mediators {#sec2dot7-nutrients-12-01933}
-------------------------------

Serum nitric oxide (NO) and hydrogen peroxide (H~2~O~2~) were measured by enzyme immunoassay and colorimetric methods using the Oxis Research kits (USA). NO and H~2~O~2~ detection limits were estimated at 0.5 µmol/L and 6.25 µmol/L, respectively. C-reactive protein (CRP) concentration was determined using commercial kit from DRG International (USA) with the detection limit 0.001 mg/L.

2.8. Growth Factors {#sec2dot8-nutrients-12-01933}
-------------------

Serum hepatocyte growth factor (HGF), insulin-like growth factor (IGF-1), muscle isoform of platelet-derived growth factor (PDGF^BB^), vascular endothelial growth factor (VEGF) and brain-derived neutrophic factor (BDNF) were evaluated by R&D Systems ELISA kits (USA). Detection limits were estimated at 40 pg/mL, 0.026 ng/mL, 15 pg/mL, 9 pg/mL and 20 pg/mL, respectively.

2.9. Lipoprotein-Lipid Profile {#sec2dot9-nutrients-12-01933}
------------------------------

Total cholesterol (TC), high-density lipoproteins (HDL) and low-density lipoproteins (LDL) as well as triglycerides (TG) were determined by professional laboratory company Diagnostyka (Poland, ISO 15189). The non-HDL cholesterol was calculated by subtracting HDL from total cholesterol concentration.

2.10. Haematological Variables {#sec2dot10-nutrients-12-01933}
------------------------------

The haematological markers (HB, RBC, RET, HTC, MCV, MCH, MCHC, RDW) and white blood cells (WBC) were determined by Diagnostyka (Poland, ISO 15189). Erythropoietin (EPO) was determined by enzyme immunoassay methods using the R&D Systems kits (USA). The detection limit for EPO was estimated at 0.6 mlU/mL.

2.11. Statistical Analysis {#sec2dot11-nutrients-12-01933}
--------------------------

Statistical analyses were performed using the R system, version 3.6.1 \[<https://www.r-project.org>\]. The significant differences in mean values between the groups (Control, Arg, IHE and Arg/IHE) were assessed mainly by the one-way ANOVA and the Tukey's post hoc tests. The assumptions for the use of parametric or non-parametric tests were checked using the Shapiro--Wilk and the Levene tests to evaluate the normality of the distributions and the homogeneity of variances, respectively. The significant differences for NO and H~2~O~2~ were assessed first by the one-way MANOVA. A statistically significant one-way MANOVA can be followed up by univariate one-way ANOVA examining, separately, each dependent variable. Moreover, the appropriate multivariate tests for checking assumptions were used (i.e., multivariate normality and homogeneity of variance-covariance matrices). In the case of ANOVA, if the normality and homogeneity assumptions were violated, the Kruskal--Wallis non-parametric test was used. The comparisons of repeated measurements (1st vs. 7th and 1st vs. 14th days of the camp) were assessed by the t-Student test or the Wilcoxon signed-rank test depending on compliance with the normality assumption. Additionally, eta-squared (*η*^2^) was used as a measure of effect size, which is indicated as having no effect if 0 ≤ *η*^2^ \< 0.05, a minimum effect if 0.05 ≤ *η*^2^ \< 0.26, a moderate effect if 0.026 ≤ *η*^2^ \< 0.64 and a strong effect if *η*^2^ ≥ 0.64 \[[@B16-nutrients-12-01933]\]. Pearson's correlation coefficients were calculated to describe the relationships between CK, NO, H~2~O~2~ and growth factors. Statistical significance was set at *P* \< 0.05.

3. Results {#sec3-nutrients-12-01933}
==========

3.1. Skeletal Muscle Damage {#sec3dot1-nutrients-12-01933}
---------------------------

CK activity reached 2-fold increase on the 7th day and 14th days of the conditioning camp in controls and Arg whereby %CK did not significantly differ between groups. The hypoxic exposure increased %CK activity significantly by 357 ± 78% on the 7th day and by 684 ± 117% on the 14th day in IHE and by 263 ± 159% on the 7th day and by 586 ± 270% on the 14th day compared to the 1st day of the training camp in Arg/IHE group. However, CK did not reach the values \>3000 IU/L, which were observed following very intensive training in our previous study \[[@B17-nutrients-12-01933]\]. The total CK activity highly correlated with NO (r = 0.720, *P* \< 0.001) and H2O2 (r = 0.646, *P* \< 0.001). This indicates that hypoxia-induced generation of reactive oxygen and nitrogen species increases skeletal muscles damage.

3.2. Oxi-Inflammatory Mediators {#sec3dot2-nutrients-12-01933}
-------------------------------

The results are presented in [Table 2](#nutrients-12-01933-t002){ref-type="table"}. The changes in NO and H~2~O~2~ concentrations proceeded simultaneously and reached the highest values on the last day of the training camp ([Figure 2](#nutrients-12-01933-f002){ref-type="fig"}, [Figure 3](#nutrients-12-01933-f003){ref-type="fig"} and [Figure 4](#nutrients-12-01933-f004){ref-type="fig"}). The hypoxic exposure resulted in above 2-fold increase in NO and H~2~O~2~ concentration on the 7th day of the training camp, and during the following days NO and H~2~O~2~ remained at a high level in IHE and Arg/IHE groups. The NO/H~2~O~2~ ratio decreased in IHE and Arg/IHE compared to control group, which indicates a more significant influence of intermittent hypoxia on H~2~O~2~ than on NO generation. The value η^2^ showed a strong effect of arginine and/or IHE on NO and H~2~O~2~ concentrations on the 7th and 14th days of observation, i.e., the time of arginine and/or IHE administration determined the extent of changes in both molecules. CRP concentration significantly increased in response to hypoxic exposure in IHE and Arg/IHE compared with control on the 7th day, but it remained on the level \<5 mg/L. Since the increased CRP level did not exceed the reference values, we concluded that hypoxic exposure applied in our study did not adversely affect the athletes' inflammatory status.

3.3. Growth Factors {#sec3dot3-nutrients-12-01933}
-------------------

The results are presented in [Table 3](#nutrients-12-01933-t003){ref-type="table"}. The changes in circulating growth factors levels proceeded differently following sports training and arginine intake, and they were dependent on skeletal muscle damage. The levels of PDGFBB, BDNF and VEGF increased on the 7th day; HGF level rose on the 14th day whereas IGF-1 decreased in controls and Arg. Hypoxic exposure elevated growth factors except for BDNF, which significantly decreased on the 7th and 14th days compared to the initial level and control group. NO and H~2~O~2~ generation significantly modulated the release of growth factors into the circulation. The strongest association was observed for NO, H~2~O~2~ and IGF-1 ([Table 4](#nutrients-12-01933-t004){ref-type="table"}). The value η^2^ indicated a strong effect of arginine and/or IHE administration on growth factors concentrations, particularly on the 14th day of observation. This means that the duration of use of arginine and hypoxia determine the extent of the changes in growth factors, similarly to nitric oxide.

3.4. Haematological Variables {#sec3dot4-nutrients-12-01933}
-----------------------------

The results are presented in [Table 5](#nutrients-12-01933-t005){ref-type="table"}. No changes in HB concentration were observed whereas contrasting changes were identified in other haematological markers, i.e., RBC and HTC levels decreased while RET concentration increased in all subjects during the 14-day observation. The serum EPO level rose significantly in all subjects on the 7th and 14th days. However, what hypoxia exposure, alone or with arginine intake, exerted the greatest influence on was EPO concentration. EPO level highly correlated with NO (r = 0.624, *P* \< 0.001) and H~2~O~2~ (r = 0.600, *P* \< 0.001), which indicates their substantial share in erythropoietin synthesis. A moderate effect of arginine and/or IHE administration on EPO concentration was also proven by the value η^2^. WBC count increased on the 14th day of the training camp in all subjects but fell within the normal range (from 4.0 × 10^3^/µL to 10.0 × 10^3^/µL). Therefore, we concluded that arginine intake and/or hypoxic exposure applied in our study did not adversely affect the athletes' immune function.

3.5. Lipoprotein--Lipid Profile {#sec3dot5-nutrients-12-01933}
-------------------------------

The results are presented in [Table 6](#nutrients-12-01933-t006){ref-type="table"}. TG, TC, LDL and HDL concentrations were found to be at similar levels in all subjects. On the 1st day of observation, high levels of TC and LDL were detected in 40% (\>200 mg/dL) and 31% (\>130 mg/dL) of the subjects, respectively. Finally, non-HDL exceeded the level of 145 mg/dL in 40% of the athletes. A decreasing trend of all the elements of lipid profile was observed on 14th day in Arg and IHE when compared to control group. Interestingly, hypoxic exposure induced approx. 20% decrease in non-HDL on the 7th and 14th days compared to the 1st day of sports training. The value η2 showed a moderate impact of arginine and/or IHE administration on non-HDL concentration, especially on the 14th day of the observation.

4. Discussion {#sec4-nutrients-12-01933}
=============

Skeletal muscle regeneration is a complex event that includes changes in generation of reactive and oxygen species, interactions between skeletal muscle and the immune system as well as satellite cells activation \[[@B18-nutrients-12-01933]\]. In sports medicine, the efficiency of regenerative processes is decisive for athletes' health and physical performance. Therefore, new therapies are being sought to modify the cascade of injury--repair--regeneration of skeletal muscles. In many cases, regeneration-stimulating methods are implemented into clinical medicine to improve functional abilities in patients awaiting surgical interventions or suffering from chronic illnesses such as cardiovascular and rheumatic diseases \[[@B4-nutrients-12-01933],[@B8-nutrients-12-01933],[@B13-nutrients-12-01933],[@B19-nutrients-12-01933],[@B20-nutrients-12-01933],[@B21-nutrients-12-01933],[@B22-nutrients-12-01933]\]. NO and H~2~O~2~ production is known to increase dramatically in injured skeletal muscle \[[@B18-nutrients-12-01933],[@B23-nutrients-12-01933]\]. In addition, previous studies have shown that persistent inflammation after exercise-induced muscle damage is accompanied by reduced NO bioavailability and excessive H~2~O~2~ concentration \[[@B18-nutrients-12-01933],[@B24-nutrients-12-01933],[@B25-nutrients-12-01933],[@B26-nutrients-12-01933]\]. In the present study, intensive sport training significantly elevated NO and H~2~O~2~ concentrations but lowered NO/H~2~O~2~ ratio, which indicates H~2~O~2~ overproduction compared to NO. Hypoxic exposure enhanced H~2~O~2~ concentration on the 7th day and NO level on the 14th day of training camp in IHE and Arg/IHE. A large number of studies have demonstrated that intermittent hypoxia increases the production of both molecules in a variety of model systems, including cells, blood vessels, muscles and isolated hearts \[[@B27-nutrients-12-01933],[@B28-nutrients-12-01933],[@B29-nutrients-12-01933],[@B30-nutrients-12-01933],[@B31-nutrients-12-01933]\]. Under conditions which amplify or prolong the initial inflammatory response, manifested by CRP increase, muscle damage can be considerably increased by NO and H~2~O~2~ produced in neutrophils and macrophages by inducible nitric oxide synthase (iNOS) and NADPH oxidase (NOX). Hypoxia enhances iNOS expression in pro-inflammatory macrophages M1 which, having reached their peak concentration in injured and regenerating muscle, are then replaced by a population of M2 macrophages that can attenuate the inflammatory response and promote tissue repair \[[@B18-nutrients-12-01933]\]. Some reports have suggested that endothelial NOS expression is similarly elevated in hypoxia-exposed animals \[[@B32-nutrients-12-01933]\]. In or study, skeletal muscle damage was the primary cause of NO and H~2~O~2~ release from active immune cells. The highest levels of NO and H~2~O~2~ were observed in subjects exposed to hypoxia and who demonstrated the highest CK activity \>900 IU/L. This increase in NO and H~2~O~2~ levels strongly correlated with CK activity. Total CK activity is a widely used measurement in monitoring of the training load, physical efficacy and overtraining \[[@B17-nutrients-12-01933],[@B33-nutrients-12-01933]\]. Morris et al. \[[@B34-nutrients-12-01933]\] demonstrated that muscle damage biomarkers increased over time and exceeded the normal reference ranges at moderate altitude (hyperbaric hypoxia), indicating cell damage pathology. Hypoxia impairs injured muscles rebuilding in patients with chronic obstructive pulmonary disease and peripheral arterial disease, but it has a positive effect on the muscle regenerative capacity in athletes \[[@B7-nutrients-12-01933],[@B35-nutrients-12-01933]\]. The high dose of oral arginine, applied in our study, did not have any effect on NO and H~2~O~2~ production and muscle damage provoked by intensive training and hypoxic exposure. Similar observations have recently been reported by Alvares et al. \[[@B36-nutrients-12-01933]\], Forbes and Bell \[[@B37-nutrients-12-01933]\], Forbes et al. \[[@B38-nutrients-12-01933]\], Meirelles and Matsuura \[[@B39-nutrients-12-01933]\] and Meirelle et al. \[[@B40-nutrients-12-01933]\]. Studies in human isolated muscle and myotube culture have demonstrated that NO and H~2~O~2~ are key regulators of pre- and posttranslational signalling events leading to cytokines, heat-stress proteins and growth factors synthesis \[[@B41-nutrients-12-01933]\]. The growth factors especially involved in myogenesis include HGF, IGF-1, PDGF^BB^, VEGF and BDNF, which are released from leucocytes and muscle cells within a few hours after muscle damage and then secreted from other tissues during the following few days. The timing and availability of these growth factors, as well as their receptors density on or within the myogenic satellite cells, are critical mediators in the regenerative process \[[@B42-nutrients-12-01933]\]. In our study, the changes in circulating growth factors proceeded differently in time following sports training, arginine intake and/or hypoxic exposure; however, all the growth factors were found to be related to NO and H~2~O~2~ generation ([Table 4](#nutrients-12-01933-t004){ref-type="table"}). Hypoxic exposure was observed to elevate growth factors levels, except for BDNF, which significantly decreased on the 7th and 14th days of the training camp. The changes were more pronounced when arginine with IHE were used, especially for IGF-1 and VEGF. The value *η*^2^ indicated that arginine and/or IHE administration produced the strongest effect on IGF-1 in comparison with other growth factors. According to Oh et al. \[[@B12-nutrients-12-01933]\] arginine promotes the synthesis and secretion of IGF-1 from hepatocytes through the mitogen-activated protein kinases (MAPK) cascades that are central signalling pathways and regulate a wide variety of cellular processes, including proliferation, differentiation, apoptosis and stress response. The authors showed dual function of arginine in cellular processes. Firstly, arginine directly activated MAPK signalling cascades, as a short-term effect; secondly, it induced IGF-1 mRNA expression and subsequent secretion, as seen via a long-term treatment. Arginine transport into endothelial cells is augmented by VEGF, and this effect can be modulated by hypoxia \[[@B43-nutrients-12-01933],[@B44-nutrients-12-01933]\]. VEGF improves skeletal muscle repair through modulation of angiogenesis; however, recent studies concerning therapeutic vascularization have demonstrated that the mechanism is regulated by PDGF^BB^ \[[@B45-nutrients-12-01933]\]. In our study, the highest levels of VEGF and PDGF^BB^ were observed in the group where simultaneous use of arginine and hypoxia exposure were applied.

The regenerative process requires multiple factors to work in a coordinated way in order to restore tissue metabolic functionality. In our study, changes in NO and H~2~O~2~ caused by simultaneous Arg and IHE application were demonstrated to be associated most significantly with circulating IGF-1 and HGF, and further on with PDGF^BB^ and BDNF ([Table 4](#nutrients-12-01933-t004){ref-type="table"}). HGF has been proven to increase myogenic satellite cells migration to the site of injury and to play a prominent role in regulation of early phases of muscle regeneration. Its release from the muscle extracellular matrix is initially mediated via NO release after mechanical or injury-induced signals \[[@B46-nutrients-12-01933]\]. The BDNF, in turn, is the circulating factor which deserves special attention. This growth factor is part of the neurotrophic family and is responsible for the viability and functioning of a variety of neuronal subtypes within the brain. In skeletal muscle, BDNF is accountable for proliferation and differentiation of satellite cells as well as growth of the myofibers \[[@B47-nutrients-12-01933]\]. The available data show that almost 70--80% of circulating BDNF come from the brain and 25% from contracting muscles \[[@B48-nutrients-12-01933],[@B49-nutrients-12-01933]\]. In this study, a decrease in BDNF concentration following hypoxic exposure was observed at a similar level, approx. 40%, in both IHE and Arg/IHE groups. To date, the mechanism of hypoxia effect on the central nervous system has been poorly investigated. Some data suggest that hypoxic exposure reduces cognitive functions and modifies central motor command \[[@B50-nutrients-12-01933],[@B51-nutrients-12-01933]\]. However, Piotrowicz et al. \[[@B52-nutrients-12-01933]\] recently demonstrated that neurotrophins, which are considered as brain damage markers, were not affected by hypoxic conditions, which proves IHE safety for the central nervous system.

NO and H~2~O~2~ are involved in signal transduction pathways as part of the O~2~-sensing mechanism stabilizing transcription factor HIF-1 and regulating erythropoietin expression. EPO regulates the process of haematopoiesis, stabilizes vascular integrity, increases the number of endothelial cells and protects these cells against ischemia and apoptosis \[[@B52-nutrients-12-01933],[@B53-nutrients-12-01933]\]. According to Jia et al. \[[@B54-nutrients-12-01933]\] EPO contributes directly to myoblast proliferation and survival, leading to muscle regeneration and repair. The EPO expression during hypoxia is more dependent on changes in H~2~O~2~, whereas in non-hypoxic conditions it is related to NO, pro-inflammatory cytokines IL-β and TNFα as well as growth factors \[[@B55-nutrients-12-01933]\]. In this study, hypoxic exposure, alone or with arginine intake, was found to have a significant impact on serum EPO level in relation to H~2~O~2~ and NO during a 14-day observation. It has been described that HIF-1 transcriptional activity and EPO expression are achieved through two parallel mechanisms, i.e., a decrease in O~2~-dependent hydroxylation of HIF-1 and S-nitrosylation of HIF-1 pathway components \[[@B30-nutrients-12-01933]\]. Beleslin-Cokic et al. \[[@B56-nutrients-12-01933]\] provided evidence that hypoxia and EPO increased the endothelial cells capacity of NO production.

The mechanisms involved in the generation of reactive oxygen and nitrogen species are critical for endothelial function \[[@B30-nutrients-12-01933]\]. The NO and H~2~O~2~ overproduction as well as nitration of many proteins cause a decrease of enzyme activity, disrupt metabolism and cellular detoxification, impair cytoskeletal organization and ultimately contribute to the cytotoxic effects of peroxynitrite. Interestingly, in this study, arginine and/or hypoxic exposure was observed to induce a decrease in non-HDL by approx. 20% on the 7th and 14th days compared to the 1st day of sports training. Other elements of lipid profile tended to decrease when compared to controls. According to Bailey et al. \[[@B4-nutrients-12-01933]\] and Mallet et al. \[[@B57-nutrients-12-01933]\], intermittent hypoxic exposure increases cardiovascular resistance to ischemia-reperfusion stress and can be safely used clinically to protect subjects with developing coronary disease or those awaiting cardiac procedures. In sport, intermittent hypoxic exposure is commonly used to increase physical performance. However, our study demonstrated that IHE alone or in combination with arginine can simultaneously enhance regenerative capacity of skeletal muscle and protect athletes from endothelial dysfunction, especially the athletes participating in sports that include strength elements.

5. Conclusions {#sec5-nutrients-12-01933}
==============

In this study we demonstrated for the first time that intermittent hypoxic exposure and high arginine intake collectively contribute to the release of mediators that regulate the injury--repair--regeneration of skeletal muscles and endothelium. Therefore, simultaneous application of IHE and arginine seems to have favourable and therapeutic potential to modulate the myogenesis and angiogenesis, especially in athletes undergoing strenuous training schedule. However, the transfer of hypoxic exposure with arginine intake to a clinical setting to enhance skeletal muscles repair or to reduce an endothelial dysfunction requires further studies.

6. Limitations {#sec6-nutrients-12-01933}
==============

The limitations of the study include a relatively small number of subjects and no continuation of experiment after the training camp; however, it proved sufficient to show a protective effect of hypoxic exposure and arginine intake in elite athletes typically engaged in very high-intensity exercise training. Moreover, few epidemiologic and physiologic observations in athletes make it difficult to explain the impact of simultaneous application of IHE and arginine on the tissue regeneration.
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![Visualisation of the MANOVA statistical analysis of changes in nitric oxide (NO) and hydrogen peroxide (H~2~O~2~) levels on the 14th day of the training camp for the following groups: control, arginine (Arg), hypoxic exposure (IHE) and arginine with hypoxic exposure (Arg/IHE). Results of the Tukey HSD post-hoc comparisons are coded as follows: \* *P* \< 0.05, \*\*\* *P* \< 0.001, \*\*\*\* *P* \< 0.0001. The homogeneity of covariances and multivariate normality assumptions are met.](nutrients-12-01933-g004){#nutrients-12-01933-f004}
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###### 

Anthropometrics and body composition (mean ± SD).

  -------------------------------------------------------------------------------------------------------
                    Control\      Arg\          IHE\          Arg/IHE\      Control vs. Arg IHE Arg/IHE
                    *n* = 10      *n* = 7       *n* = 6       *n* = 9       
  ----------------- ------------- ------------- ------------- ------------- -----------------------------
  Age \[yr.\]       24.6 ± 3.0    20.0 ± 1.6    22.8 ± 2.6    24.7 ± 4.4    \<0.05\
                                                                            0.622\
                                                                            0.999

  Height \[cm\]     173.6 ± 8.8   179.0 ± 9.5   181.2 ± 7.3   175.6 ± 8.3   0.559\
                                                                            0.320\
                                                                            0.947

  Weight \[kg\]     81.4 ± 21.8   79.9 ± 13.0   97.1 ± 22.7   87.9 ± 20.7   0.989\
                                                                            0.560\
                                                                            0.957

  BMI \[kg/m^2^\]   26.6 ± 4.5    24.4 ± 1.4    29.3 ± 5.2    27.8 ± 4.5    0.552\
                                                                            0.773\
                                                                            0.990

  %FM               18.1 ± 4.8    9.3 ± 3.0     14.5 ± 6.0    21.3 ± 6.5    \<0.05\
                                                                            0.844\
                                                                            0.252

  FM \[kg\]         15.4 ± 7.4    7.6 ± 3.2     15.1 ± 9.5    19.3 ± 10.8   0.355\
                                                                            0.998\
                                                                            0.569

  FFM \[kg\]        66.0 ± 15.0   72.3 ± 10.6   81.9 ± 14.0   67.2 ± 11.5   0.952\
                                                                            0.270\
                                                                            0.996
  -------------------------------------------------------------------------------------------------------

**Abbreviations**: Arg, arginine intake; IHE, intermittent hypoxic exposure; Arg/IHE, arginine intaken and intermittent hypoxic exposure; BMI, body mass index; FM, fat mass; FFM, fat-free mass. The significant differences in mean values between the groups (Control vs. Arg, Control vs. IHE, Control vs. Arg/IHE were assessed by the one-way ANOVA and Tukey's post hoc test.
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###### 

The levels of oxi-inflammatory mediators.

                                     1st Day of Camp   7th Day of Camp   14th Day of Camp   1st Day vs. 7th Day   1st Day vs. 14th Day                                                        
  ---------------------------------- ----------------- ----------------- ------------------ --------------------- ---------------------- --------- -------------- --------- ------- --------- --------
  **NO** \[µmol/L\]                                                                                                                                                                           
  Control                            15.37 ± 1.83      \-                0.166              15.36 ± 1.26          \-                     0.569     17.33 ± 0.99   \-        0.701   0.995     \<0.05
  Arg                                15.64 ± 1.66      0.98              17.67 ± 1.19       \<0.01                18.97 ± 1.67           0.326     \<0.01         \<0.01                      
  IHE                                14.78 ± 0.79      0.856             18.71 ± 0.73       \<0.001               22.26 ± 0.95           \<0.001   \<0.05         \<0.001                     
  Arg/IHE                            14.12 ± 0.95      0.251             18.67 ± 1.78       \<0.001               23.93 ± 3.02           \<0.001   \<0.001        \<0.01                      
  **H~2~O~2~** \[µmol/L\]                                                                                                                                                                     
  Control                            13.16 ± 1.13      \-                0.382              16.67 ± 2.00          \-                     0.92      17.87 ± 3.15   \-        0.678   \<0.001   \<0.01
  Arg                                13.39 ± 1.76      0.992             13.99 ± 3.66       0.46                  17.34 ± 4.45           0.994     0.748          \<0.05                      
  IHE                                15.26 ± 1.99      0.098             40.36 ± 4.64       \<0.001               30.93 ± 4.81           \<0.001   \<0.001        \<0.001                     
  Arg/IHE                            15.97 ± 1.91      \<0.01            39.47 ± 4.36       \<0.001               27.41 ± 4.63           \<0.001   \<0.001        \<0.001                     
  **NO/H~2~O~2~ ratio** \[µmol/L\]                                                                                                                                                            
  Control                            1.17 ± 0.10       \-                0.456              0.93 ± 0.13           \-                               0.99 ± 0.15    \-        0.386   \<0.01    \<0.05
  Arg                                1.19 ± 0.23       0.986             1.35 ± 0.42        \<0.01                1.13 ± 0.19            0.383     0.505          0.675                       
  IHE                                0.98 ± 0.13       0.095             0.47 ± 0.05        \<0.01                0.74 ± 0.15            \<0.05    \<0.001        \<0.05                      
  Arg/IHE                            0.90 ± 0.12       \<0.01            0.51 ± 0.10        \<0.01                0.90 ± 0.20            0.615     \<0.001        0.974                       
  **CRP** \[mg/L\]                                                                                                                                                                            
  Control                            1.57 ± 0.53       \-                0.024              2.02 ± 0.35           \-                     0.552     2.29 ± 0.48    \-        0.115   \<0.05    \<0.01
  Arg                                1.62 ± 0.49       0.997             1.99 ± 0.55        0.999                 2.14 ± 0.41            0.917     0.182          0.097                       
  IHE                                1.45 ± 0.15       0.968             2.69 ± 0.41        \<0.05                2.46 ± 0.28            0.913     \<0.001        \<0.001                     
  Arg/IHE                            1.66 ± 0.57       0.977             3.09 ± 0.52        \<0.001               2.58 ± 0.63            0.589     \<0.001        \<0.01                      

**Abbreviations:** NO, nitric oxide; H2O2, hydrogen peroxide; CRP, C-reactive protein; η2 is a measure of effect size. Data in columns whose names begin with "Control" show the P-values of the Tukey's post-hoc tests of the univariate one-way ANOVA examining, separately, each dependent variable. The last two columns show the P-values of the t-Student test or the Wilcoxon nonparametric test (if the normality assumption is violated).
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###### 

The levels of tissue regeneration mediators.

                         1st Day of Camp   7th Day of Camp   14th Day of Camp   1st Day vs. 7th Day   1st Day vs. 14th Day                                                        
  ---------------------- ----------------- ----------------- ------------------ --------------------- ---------------------- --------- --------------- --------- ------- -------- ---------
  **HGF \[pg/mL\]**                                                                                                                                                               
  Control                587 ± 73          \-                0.237              534 ± 77              \-                     0.467     602 ± 68        \-        0.653   \<0.01   0.625
  Arg                    620 ± 60          0.687             568 ± 89           0.827                 770 ± 69               \<0.001   \<0.05          \<0.01                     
  IHE                    623 ± 61          0.666             546 ± 95           0.992                 792 ± 49               \<0.001   0.094           \<0.05                     
  Arg/IHE                544 ± 42          0.425             708 ± 72           \<0.001               789 ± 71               \<0.001   \<0.001         \<0.001                    
  **IGF-1** \[ng/mL\]                                                                                                                                                             
  Control                120 ± 41          \-                0.19               116 ± 22              \-                     0.867     100 ± 15        \-        0.911   0.16     0.084
  Arg                    126 ± 23          0.982             103 ± 19           0.834                 98 ± 12                0.998     0.073           \<0.01                     
  IHE                    149 ± 11          0.231             248 ± 26           \<0.001               206 ± 29               \<0.001   \<0.001         \<0.01                     
  Arg/IHE                148 ± 26          0.186             280 ± 51           \<0.001               293 ± 43               \<0.001   \<0.001         \<0.001                    
  **PDGFBB** \[pg/mL\]                                                                                                                                                            
  Control                2281 ± 513        \-                0.084              2646 ± 289            \-                     0.381     2068 ± 368      \-        0.706   0.074    0.063
  Arg                    2327 ± 418        0.995             2836 ± 293         0.806                 1980 ± 161             0.927     0.062           0.088                      
  IHE                    2582 ± 231        0.456             2762 ± 160         0.953                 3133 ± 263             \<0.001   0.15            \<0.01                     
  Arg/IHE                2307 ± 266        0.999             3418 ± 686         \<0.01                2478 ± 274             \<0.05    \<0.01          0.226                      
  **BDNF** \[pg/mL\]                                                                                                                                                              
  Control                23,447 ± 3237     \-                0.067              27,486 ± 1974         \-                     0.781     27,426 ± 2452   \-        0.789   \<0.05   \<0.01
  Arg                    23,922 ± 3040     0.987             29,567 ± 2651      0.301                 26,626 ± 1250          0.88      \<0.05          0.073                      
  IHE                    22,402 ± 3184     0.899             18,817 ± 1118      \<0.001               18,154 ± 1377          \<0.001   0.059           0.053                      
  Arg/IHE                22,120 ± 2177     0.756             21,218 ± 3025      \<0.001               19,952 ± 2791          \<0.001   0.198           \<0.05                     
  **VEGF** \[pg/mL\]                                                                                                                                                              
  Control                341 ± 68          \-                0.03               405 ± 54              \-                     0.112     234 ± 65        \-        0.782   0.085    \<0.001
  Arg                    361 ± 64          0.861             408 ± 63           0.958                 238 ± 77               0.999     0.154           \<0.05                     
  IHE                    330 ± 44          0.999             406 ± 46           0.974                 389 ± 45               \<0.001   \<0.05          0.135                      
  Arg/IHE                344 ± 78          0.991             452 ± 97           0.284                 495 ± 64               \<0.001   0.054           \<0.01                     

**Abbreviations**: Arg, arginine supplementation; IHE, intermittent hypoxic exposure; Arg/IHE, arginine supplementation and intermittent hypoxic exposure; HGF, hepatocyte growth factor; IGF-1, insulin-like growth factor 1β; PDGF^BB^, platelet-derived growth factor; BDNF, brain-derived neurotrophic factor; VEGF, vascular endothelial growth factor; η^2^ is a measure of effect size. Data in columns whose names begin with "Control" show the P-values of the Tukey's post-hoc tests of the univariate one-way ANOVA examining, separately, each dependent variable. The last two columns show the P-values of the t-Student test or the Wilcoxon nonparametric test (if the normality assumption is violated).
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###### 

Relationships (Pearson's correlation coefficients) between oxi-inflammatory mediators NO and H~2~O~2~, and growth factors HGF, IGF-1, PDGF^BB^, BDNF and VEGF.

                            HGF \[pg/mL\]   IGF-1 \[ng/mL\]   PDGF^BB^ \[pg/mL\]   BDNF \[pg/mL\]   VEGF \[pg/mL\]
  ------------------------- --------------- ----------------- -------------------- ---------------- ----------------
  **NO** \[µmol/L\]         0.662           0.554             0.160                −0.286           0.274
  \<0.001                   \<0.001         \>0.05            \<0.01               \<0.01           
  **H~2~O~2~** \[µmol/L\]   0.321           0.780             0.479                −0.525           0.368
  \<0.01                    \<0.001         \<0.001           \<0.001              \<0.001          
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###### 

Haematological markers and immune cells count.

                          1st Day of Camp   7th Day of Camp   14th Day of Camp   1st Day vs. 7th Day   1st day vs. 14th day                                                      
  ----------------------- ----------------- ----------------- ------------------ --------------------- ---------------------- --------- ------------- --------- ------- -------- ---------
  **HB \[g/dL\]**                                                                                                                                                                
  Control                 15.3 ± 0.8        \-                0.043              15.2 ± 0.7            \-                     0.165     15.5 ± 0.2    \-        0.462   0.918    0.335
  Arg                     14.9 ± 0.8        0.757             14.8 ± 0.5         0.617                 14.6 ± 0.3             \<0.01    0.271         0.306                      
  IHE                     15.1 ± 0.8        0.961             14.4 ± 1.0         0.137                 14.3 ± 0.6             \<0.01    0.071         0.218                      
  Arg/IHE                 15.3 ± 0.7        1                 15.1 ± 0.7         0.947                 15.2 ± 0.8             0.517     0.16          0.851                      
  **RBC** \[mln/mm^3^\]                                                                                                                                                          
  Control                 5.4 ± 0.3         \-                0.189              5.4 ± 0.2             \-                     0.392     5.1 ± 0.2     \-        0.736   0.411    \<0.05
  Arg                     5.3 ± 0.5         0.781             5.2 ± 0.3          0.286                 4.6 ± 0.1              \<0.001   0.636         \<0.05                     
  IHE                     5.2 ± 0.4         0.852             5.0 ± 0.5          \<0.05                4.7 ± 0.3              \<0.01    0.055         \<0.05                     
  Arg/IHE                 5.0 ± 0.2         0.076             4.9 ± 0.2          \<0.01                5.5 ± 0.3              \<0.05    0.065         \<0.01                     
  **RET** \[‰\]                                                                                                                                                                  
  Control                 4.1 ± 1.1         \-                0.222              5.2 ± 1.2             \-                     0.459     7.1 ± 2.2     \-        0.505   \<0.05   \<0.01
  Arg                     4.1 ± 1.2         1                 5.0 ± 1.4          0.994                 10.1 ± 1.8             \<0.05    0.2           \<0.001                    
  IHE                     3.0 ± 0.6         0.139             8.7 ± 2.5          \<0.001               12.0 ± 1.4             \<0.001   \<0.01        \<0.001                    
  Arg/IHE                 3.3 ± 0.7         0.295             6.4 ± 1.1          0.319                 9.3 ± 1.7              0.071     \<0.001       \<0.01                     
  **HCT** \[%\]                                                                                                                                                                  
  Control                 48.1 ± 3.0        \-                0.4                48.2 ± 2.8            \-                     0.45      45.8 ± 1.5    \-        0.403   0.825    \<0.05
  Arg                     47.9 ± 3.0        0.996             47.2 ± 1.8         0.878                 43.0 ± 1.2             \<0.01    0.444         \<0.01                     
  IHE                     45.7 ± 1.1        0.221             45.1 ± 2.4         0.164                 44.2 ± 2.4             0.176     0.598         0.096                      
  Arg/IHE                 43.8 ± 1.7        \<0.01            42.3 ± 3.7         \<0.001               45.8 ± 1.0             1         0.41          \<0.05                     
  **MCV** \[fL\]                                                                                                                                                                 
  Control                 89.3 ± 3.9        \-                0.316              89.9 ± 3.1            \-                     0.427     89.8 ± 2.0    \-        0.732   0.43     0.626
  Arg                     92.1 ± 3.0        0.35              91.8 ± 2.8         0.559                 93.5 ± 0.3             \<0.05    0.647         0.278                      
  IHE                     85.5 ± 3.4        0.163             84.8 ± 2.4         \<0.05                83.8 ± 1.9             \<0.001   0.328         0.067                      
  Arg/IHE                 88.0 ± 3.2        0.842             87.8 ± 3.1         0.406                 85.0 ± 3.5             \<0.001   0.681         \<0.05                     
  **MCH** \[pg/RBC\]                                                                                                                                                             
  Control                 28.4 ± 1.0        \-                0.393              28.5 ± 1.5            \-                     0.311     30.5 ± 0.9    \-        0.643   1        \<0.001
  Arg                     28.7 ± 1.5        0.963             28.6 ± 0.9         1                     32.0 ± 0.6             \<0.05    1             \<0.001                    
  IHE                     28.8 ± 1.4        0.934             29.7 ± 1.9         0.377                 28.5 ± 1.0             \<0.01    0.079         0.451                      
  Arg/IHE                 30.7 ± 1.2        \<0.01            30.6 ± 1.1         \<0.05                28.6 ± 1.5             \<0.01    0.681         \<0.05                     
  **MCHC** \[g/dL\]                                                                                                                                                              
  Control                 31.7 ± 0.9        \-                0.826              31.7 ± 1.1            \-                     0.863     33.7 ± 0.4    \-        0.158   0.968    \<0.01
  Arg                     31.0 ± 0.6        0.241             31.2 ± 0.3         0.522                 34.2 ± 0.3             0.221     0.359         \<0.05                     
  IHE                     33.5 ± 0.2        \<0.001           35.1 ± 0.9         \<0.001               33.7 ± 0.6             1         \<0.001       0.336                      
  Arg/IHE                 34.8 ± 0.8        \<0.001           34.9 ± 0.3         \<0.001               33.8 ± 0.5             1         0.155         \<0.05                     
  **RDW** \[%\]                                                                                                                                                                  
  Control                 15,2 ± 1,7        \-                0.525              15.0 ± 1.3            \-                     0.594     15,0 ± 0.9    \-        0.85    0.797    0.743
  Arg                     14,7 ± 0.4        0.839             14.9 ± 0.6         0.973                 14.5 ± 0.0             0.282     0.352         0.26                       
  IHE                     12.4 ± 0.4        \<0.001           12.4 ± 0.4         \<0.001               12.4 ± 0.3             \<0.001   0.741         0.618                      
  Arg/IHE                 15.3 ± 0.9        0.991             14.9 ± 0.6         0.975                 12.3 ± 0.4             \<0.001   0.214         \<0.001                    
  **EPO** \[mIU/mL\]                                                                                                                                                             
  Control                 3.25 ± 0.88       \-                0.618              4.3 ± 1.37            \-                     0.466     4.84 ± 1.17   \-        0.654   \<0.01   \<0.01
  Arg                     3.51 ± 0.42       0.922             6.08 ± 1.04        \<0.05                4.40 ± 1.68            0.994     0.618         \<0.05                     
  IHE                     3.12 ± 0.86       0.99              6.57 ± 0.71        \<0.01                9.70 ± 2.32            \<0.001   \<0.01        \<0.001                    
  Arg/IHE                 4.62 ± 0.8        \<0.01            6.49 ± 0.73        \<0.01                8.13 ± 1.62            \<0.001   \<0.001       \<0.01                     
  **WBC** \[10^3^/µL\]                                                                                                                                                           
  Control                 5.9 ± 1.0         \-                0.149              6.7 ± 0.7             \-                     0.25      6.9 ± 0.4     \-        0.173   0.066    \<0.05
  Arg                     5.6 ± 0.1         0.774             5.9 ± 0.8          0.3                   6.5 ± 0.8              0.957     0.281         \<0.05                     
  IHE                     5.0 ± 0.3         0.148             5.3 ± 0.7          \<0.05                6.1 ± 0.3              0.619     0.114         \<0.01                     
  Arg/IHE                 5.5 ± 1.0         0.654             6.2 ± 1.2          0.699                 7.6 ± 2.2              0.591     0.322         \<0.05                     

**Abbreviations**: Arg, arginine supplementation; IHE, intermittent hypoxic exposure; Arg/IHE, arginine supplementation and intermittent hypoxic exposure; HB, haemoglobin; RBC, red blood cells; RET, reticulocytes; HCT, haematocrit; MCV, mean cell volume; MCH, mean corpuscular haemoglobin; MCHC, mean corpuscular haemoglobin concentration; RDW, red cell distribution width; EPO, erythropoietin; WBC, white blood cell count; η^2^ is a measure of effect size. Data in columns whose names begin with "Control" show the P-values of the Tukey's post-hoc tests of the univariate one-way ANOVA examining, separately, each dependent variable. The last two columns show the P-values of the t-Student test or the Wilcoxon nonparametric test (if the normality assumption is violated).
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###### 

Lipoprotein--lipid profile.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                          1st Day of Camp   7th Day of Camp   14th Day of Camp   1st Day vs. 7th Day   1st Day vs. 14th Day                                                  
  ----------------------- ----------------- ----------------- ------------------ --------------------- ---------------------- -------- ---------- --------- ------- -------- --------
  **TG** \[mg/dL\]                                                                                                                                                           

  Control                 97 ± 34           \-                0.057              83 ± 24               \-                     0.231    118 ± 42   \-        0.359   \<0.05   0.31

  Arg                     85 ± 24           0.925             76 ± 12            0.951                 64 ± 4                 \<0.01   0.331      0.057                      

  IHE                     111 ± 41          0.898             112 ± 18           0.138                 122 ± 27               0.995    0.975      0.357                      

  Arg/IHE                 105 ± 50          0.969             78 ± 35            0.978                 111 ± 32               0.964    0.06       0.764                      

  **TC** \[mg/dL\]                                                                                                                                                           

  Control                 196 ± 25          \-                0.143              189 ± 38              \-                     0.315    175 ± 19   \-        0.306   0.323    \<0.05

  Arg                     160 ± 47          0.238             138 ± 25           \<0.05                148 ± 7                0.123    0.097      0.522                      

  IHE                     188 ± 38          0.976             161 ± 31           0.399                 163 ± 27               0.789    \<0.05     \<0.05                     

  Arg/IHE                 196 ± 41          1                 189 ± 34           1                     188 ± 30               0.601    0.399      0.359                      

  **LDL** \[mg/dL\]                                                                                                                                                          

  Control                 118 ± 27          \-                0.149              121 ± 33              \-                     0.173    111 ± 18   \-        0.059   0.707    0.232

  Arg                     93 ± 32           0.395             77 ± 17            0.555                 97 ± 10                0.692    0.094      0.698                      

  IHE                     112 ± 38          0.985             103 ± 38           0.956                 105 ± 37               0.963    0.406      0.386                      

  Arg/IHE                 128 ± 35          0.913             157 ± 117          0.664                 112 ± 30               0.999    0.432      0.129                      

  **HDL**\                                                                                                                                                                   
  \[mg/dL\]                                                                                                                                                                  

  Control                 64 ± 43           \-                0.094              51 ± 11               \-                     0.114    53 ± 10    \-        0.188   0.234    0.76

  Arg                     50 ± 13           0.716             45 ± 9             0.675                 53 ± 5                 0.996    0.182      0.47                       

  IHE                     45 ± 10           0.498             56 ± 12            0.787                 48 ± 7                 0.667    \<0.01     \<0.05                     

  Arg/IHE                 47 ± 7            0.493             49 ± 7             0.998                 45 ± 8                 0.176    \<0.05     0.641                      

  **Non-HDL** \[mg/dL\]                                                                                                                                                      

  Control                 132 ± 44          \-                0.126              138 ± 36              \-                     0.312    122 ± 15   \-        0.385   1        0.454

  Arg                     110 ± 35          1                 92 ± 17            \<0.05                95 ± 2                 0.105    0.084      0.298                      

  IHE                     143 ± 42          1                 106 ± 39           0.234                 116 ± 28               0.951    \<0.05     \<0.001                    

  Arg/IHE                 149 ± 40          1                 139 ± 31           1                     143 ± 33               0.215    0.205      0.313                      
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations**: Arg, arginine supplementation; IHE, intermittent hypoxic exposure; Arg/IHE, arginine supplementation and intermittent hypoxic exposure; TG, triglycerides; TC, total cholesterol; LDL, low-density lipoproteins; HDL, high-density lipoproteins; non-HDL, cholesterol calculated by subtracting the HDL value from a TC; η^2^ is a measure of effect size. Data in columns whose names begin with "Control" show the P-values of the Tukey's post-hoc tests of the univariate one-way ANOVA examining, separately, each dependent variable. The last two columns show the *P*-values of the t-Student test or the Wilcoxon nonparametric test (if the normality assumption is violated).
